4h
Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
Invivyd Inc (IVVD) reports robust monoclonal antibody revenue growth and strategic clinical investments, while navigating challenges in public education and regulatory uncertainties.
Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...
New HIV research reveals how broadly neutralizing antibodies may transform treatment despite the virus's rapid mutation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results